Top Page
Innovent Biologics
(OTC:1801)
Innovent Biologics (1801) vs. iShares MSCI Hong Kong ETF (EWH)
Innovent Biologics Business Overview & Revenue Model
Innovent Biologics Financial Statement Overview
| Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 9.42B | 6.21B | 4.56B | 4.27B | 3.84B |
| Gross Profit | 7.91B | 4.40B | 3.63B | 3.70B | 3.46B |
| EBITDA | -480.28M | -660.68M | -1.75B | -2.37B | -704.74M |
| Net Income | -94.63M | -1.03B | -2.18B | -3.14B | -998.42M |
Balance Sheet | |||||
| Total Assets | 21.60B | 20.63B | 17.59B | 16.24B | 11.83B |
| Cash, Cash Equivalents and Short-Term Investments | 7.88B | 10.97B | 8.26B | 7.94B | 8.05B |
| Total Debt | 2.83B | 3.62B | 3.23B | 2.50B | 1.21B |
| Total Liabilities | 8.48B | 8.10B | 6.86B | 5.91B | 3.06B |
| Stockholders Equity | 13.12B | 12.53B | 10.73B | 10.33B | 8.78B |
Cash Flow | |||||
| Free Cash Flow | -418.39M | -1.24B | -3.30B | -3.87B | -1.08B |
| Operating Cash Flow | 1.29B | 147.81M | -1.92B | -2.02B | -307.69M |
| Investing Cash Flow | -1.17B | -998.66M | -1.44B | -2.70B | -5.18B |
| Financing Cash Flow | -606.63M | 2.59B | 2.89B | 5.00B | 4.91B |
Innovent Biologics Technical Analysis
Innovent Biologics Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
76 Outperform | HK$27.31B | 30.70 | 31.65% | ― | 4.23% | 47.71% | |
74 Outperform | $102.33B | 28.37 | 8.17% | ― | 7.52% | -1.92% | |
69 Neutral | $94.79B | 49.95 | 6.14% | 11.85% | 7.63% | -24.23% | |
61 Neutral | $127.75B | ― | -0.72% | ― | 49.33% | 90.96% | |
60 Neutral | HK$15.14B | 5.55 | -7.43% | 4.78% | 11.72% | -20.69% | |
55 Neutral | HK$83.03B | ― | -8.98% | ― | -54.66% | -123.11% | |
51 Neutral | HK$33.78B | ― | -19.78% | ― | 25.96% | 39.58% |
Innovent Biologics Corporate Events
Innovent Biologics has announced that its new drug, mazdutide, a first-in-class dual GCG/GLP-1 receptor agonist, has received approval from the National Medical Products Administration of China for chronic weight management in adults with overweight or obesity. This approval marks a significant milestone as mazdutide is the world’s first dual receptor agonist for weight loss, offering enhanced efficacy and metabolic benefits. The approval aligns with China’s national health initiatives to combat the rising prevalence of obesity, which poses a substantial public health challenge. Supported by robust clinical data, mazdutide has demonstrated superior weight loss efficacy and metabolic benefits, making it a promising treatment option in the fight against obesity and its related comorbidities.
The most recent analyst rating on (HK:1801) stock is a Buy with a HK$65.98 price target. To see the full list of analyst forecasts on Innovent Biologics stock, see the HK:1801 Stock Forecast page.
Innovent Biologics, Inc. announced the placement of 55 million new shares, representing approximately 3.33% of its total shares, under a general mandate. The placement is expected to generate gross proceeds of approximately HK$4,309.8 million, with net proceeds of HK$4,265.4 million, which will be used as detailed in the company’s plans. The shares will be issued at a discount to the current market price, and the transaction is contingent upon certain conditions being met.
The most recent analyst rating on (HK:1801) stock is a Buy with a HK$65.98 price target. To see the full list of analyst forecasts on Innovent Biologics stock, see the HK:1801 Stock Forecast page.
Innovent Biologics, Inc. successfully held its Annual General Meeting on June 25, 2025, where all proposed resolutions were passed by shareholders. Key resolutions included the re-election of directors, authorization of board remuneration, re-appointment of auditors, and granting of mandates for share buybacks and issuances. The approval of these resolutions reflects strong shareholder support and positions the company for continued strategic growth and operational stability.
The most recent analyst rating on (HK:1801) stock is a Buy with a HK$65.98 price target. To see the full list of analyst forecasts on Innovent Biologics stock, see the HK:1801 Stock Forecast page.
Innovent Biologics announced that China’s National Medical Products Administration has accepted the New Drug Application for the combination of sintilimab and fruquintinib to treat advanced renal cell carcinoma. This development marks a significant step for Innovent in addressing unmet medical needs in China, further solidifying its position in the immuno-oncology sector and enhancing the clinical value of its product, TYVYT®.
The most recent analyst rating on (HK:1801) stock is a Buy with a HK$65.98 price target. To see the full list of analyst forecasts on Innovent Biologics stock, see the HK:1801 Stock Forecast page.
Innovent Biologics, Inc. has announced its upcoming annual general meeting scheduled for June 25, 2025, in Shanghai, China. Key agenda items include the re-election of directors, approval of the company’s financial statements, and authorization for share buybacks, which could impact the company’s market operations and shareholder value.
The most recent analyst rating on (HK:1801) stock is a Buy with a HK$65.98 price target. To see the full list of analyst forecasts on Innovent Biologics stock, see the HK:1801 Stock Forecast page.
Innovent Biologics reported a significant increase in product revenue for the first quarter of 2025, exceeding RMB2.4 billion, marking a growth of over 40% year-on-year. The company launched four new products, including Dovbleron, Limertinib, and Jaypirca in oncology, and SYCUME in general biomedicine, which contributed to the revenue growth. The inclusion of SINTBILO in the National Reimbursement Drug List and the launch of SYCUME for thyroid eye disease are seen as new growth drivers. Innovent’s strategic focus on sustainable growth and global innovation positions it for continued expansion in the biopharmaceutical industry.
Innovent Biologics has announced that its third-generation EGFR TKI, limertinib, has received approval from China’s National Medical Products Administration for first-line treatment of certain types of non-small cell lung cancer (NSCLC). This approval is based on positive results from a Phase 3 clinical trial, which demonstrated that limertinib significantly prolongs progression-free survival compared to gefitinib. The approval is expected to strengthen Innovent’s position in the oncology market and provide a new treatment option for patients with high-unmet needs.
Innovent Biologics, Inc. has announced changes in its board’s nomination committee and the designation of a lead independent non-executive director, effective March 31, 2025. Ms. Joyce I-Yin Hsu has been appointed as a member of the nomination committee, while Mr. Shuyun Chen has been designated as the lead independent non-executive director, reflecting the company’s ongoing efforts to strengthen its governance structure.
Innovent Biologics, Inc. has announced the composition of its board of directors, highlighting the roles and functions of each member. The board consists of both executive and independent non-executive directors, with Dr. De-Chao Michael Yu serving as the Chairman and CEO. This announcement underscores the company’s commitment to strong governance and strategic oversight, which is crucial for maintaining its competitive edge in the biopharmaceutical sector.
Innovent Biologics, Inc. has updated the terms of reference for its Nomination Committee, which was originally established in 2018. The committee’s purpose is to identify and recommend candidates for the board of directors, oversee board performance evaluations, and develop nomination guidelines in line with applicable laws and regulations. This update aims to ensure the committee’s operations align with the latest governance standards, potentially impacting the company’s strategic direction and governance practices.